|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PROTEIN AND VESICLE TRAFFICKING, CYTOSKELETON
1Biomedical Sciences Department and 2Department of Molecular Medicine, College of Veterinary Medicine, Cornell University, Ithaca, New York; and 3Department of Pharmacology and Cancer Institute, School of Medicine, Southern Illinois University, Springfield, Illinois
Submitted 5 February 2008 ; accepted in final form 18 May 2008
| ABSTRACT |
|---|
|
|
|---|
chloride channel; asthma; protein trafficking; epithelium; endoplasmic reticulum retention/trafficking signal
Posttranslational processing in the endoplasmic reticulum (ER) is critical for the proper trafficking of proteins to their cellular targets, including the plasma membrane, secretory vesicles, and other organelles (21). Proper assembly and processing occurs through the folding and glycosylation of the native peptide and the recognition of specific motifs by chaperone proteins (5). With respect to proteins that traverse the secretory pathway, specific glycosylations occur that are recognized by carbohydrate binding proteins that serve to sort and direct the peptides to the appropriate destination (10). Specific motifs regulating ER retention and forward trafficking have recently been demonstrated in the integral membrane sodium-dependent glutamate subtype glial transporter (GLT-1), consisting of dileucine (LL) pairs NH2 terminal to a diarginine (RxR) sequence (11). In the GLT-1 transporter, three LL pairs occur as part of a pattern of heptad leucines closely followed by a highly conserved RxR sequence that is conserved in glutamate transporters and found in several channel or receptor proteins (11). The former sequences regulate the forward transport of the full-length GLT-1 translation product in monomeric and multimeric forms for endosomal transport to the plasma membrane, and the latter RxR sequence serves as an ER retention motif (11).
We have used heterologous expression of tagged mCLCA4 proteins to determine the intracellular processing and cellular localization of the full-length and processed peptides. Tagged mCLCA4 proteins specific for the NH2- and COOH-terminal fragments were created that were processed in the same way as native proteins. We report that the full-length mCLCA4 proteins are cleaved into 90- and 40-kDa fragments within the ER compartment, that both peptides are secreted and associate with the plasma membrane, and that internal LL and RxR sequences serve as ER trafficking signals in mCLCA4 proteins.
| MATERIALS AND METHODS |
|---|
|
|
|---|
mCLCA4 expression. All insertions were performed by PCR-based, site-directed mutagenesis (ExSite; Strategene, La Jolla, CA). Myc insertions were expressed, and proteins were separated by gel electrophoresis to ensure proper processing of mCLCA4 to 90- and 40-kDa fragments. NH2-terminal specific tagged mutants were produced by insertion of the Myc tag between Ser21 and Ser22 (mCLCA4-21myc). COOH-terminal specific mutants were produced by inserting a Myc tag between Asn713 and Asp714 (mCLCA4-713myc). Both NH2- and COOH-terminal Myc insertion mutants were found to be processed normally. Amino acid substitutions were produced by site-directed mutagenesis of mClCA4 as previously described (16). All mutants were confirmed by DNA sequencing. To test the activity of mCLCA4 trafficking sequences, 120-bp sequences containing the putative LL and RxR trafficking signals (amino acids 565–605), or the respective mutants (2R/2A or 4L/4A), were inserted in the COOH terminus of EGFP cDNA containing the NH2-terminal hCLCA2 (secretion) signal sequence (hCLCA2ss), by PCR amplification of the pcDNA3.1Zeo vector (3) using a primer containing the putative trafficking sequences. The three DNA constructs (hCLCA2ss-EGFP-WT, 2R/2A, or 4L/4A-pcDNA3.1Zeo) were transfected into HEK293T cells as above. EGFP fluorescence was detected at 24 and 48 h, and cells were imaged using confocal (Zeiss Meta) or widefield epifluorescence (Nikon TE300) microscopes. Cell lysates were collected using the same amount of RIPA buffer, and 15 µg protein were used for immunoblot in each condition. After transfection (72 h), the media was collected for immunoprecipitation and immunoblot as described below.
Protein preparation and immunoblotting.
After 48 h transfection, cells were washed with ice-cold PBS and lysed in (150 µl) RIPA buffer (20 mM Tris buffer at pH 7.5 containing 10% glycerol, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton 100-X, 5 mM sodium β-glycerophosphate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 1 mM sodium vanadate, 0.1% SDS, 0.5% sodium deoxycholate, 1.46 µM pepstatin A, 10.5 µM leupeptin, 960 µM benzamidine, 1.53 µM aprotinin, and 570 µM phenylmethylsulfonyl fluoride). Samples were centrifuged (34,000 rpm for 30 min at 4°C) to remove insoluble cellular debris, and the supernatants were boiled in denaturing sample buffer (200 mM Tris buffer at pH 6.8 containing 8% SDS, 40% sucrose, 0.4% bromphenol blue, and 100 mM dithiothreitol) and proteins resolved by SDS-PAGE on a 10% gradient gel. Gels were electroblotted to polyvinylidene difluoride membranes, and the membranes were blocked in TBS containing 0.1% Triton X-100 and 5% nonfat dried milk. Subsequently, the membranes were immunostained with the anti-Myc antibody 4A6 (1:1,000; Upstate), anti-EGFP antibody (1:1,000; Chemicon), or anti-
-tubulin antibody (1:10,000; Sigma, St. Louis, MO), washed extensively, and then exposed to a horseradish peroxidase-conjugated goat anti-mouse secondary antibody (1:3,000; Bio-Rad, Hercules, CA). Immunoblots were visualized by enhanced chemiluminescence (Pierce Biotechnology, Rockford, IL) on a Kodak Image Station 440 (NEN Life Science Products, Boston, MA). For immunoprecipitation, culture media was collected 48 and 72 h after transfection and precleared with protein A/G-agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C for 30 min. Precleared media were then incubated overnight with an anti-Myc antibody (4A6) (1:100), followed by incubation with protein A/G-agarose beads. Protein A/G-agarose beads were washed extensively in RIPA buffer and boiled in an equal volume of 2x SDS loading buffer, followed by Western blotting as described above.
ER-Golgi transport inhibition. Posttransfection (24 h) of mCLCA4-21-Myc, HEK293T cells were washed and treated with 2 µg/ml brefeldin A (BFA; 0.02% ethanol in DMEM); control wells were washed and exposed to the same medium without BFA. BFA-treated cells were either exposed to the drug for 24 h (BFA condition), or the inhibition was reversed by wash after 4 h and exposure to 0.02% ethanol in DMEM for an additional 20 h (wash). After 24 h, the medium was collected for immunoprecipitation; cells were lysed for protein extraction, and equal concentrations of protein/sample were used for Western blotting. All experiments were performed in triplicate.
Subcellular fractionation. After transfection (48 h), cells were washed with cold PBS and scraped in 1 ml of homogenization buffer containing 250 mM sucrose, 10 mM Tris at pH 8.0, 50 mM NaF, 1.9 mM benzamidine, 1.1 mM phenylmethylsulfonyl fluoride, and 1 mM EDTA, with 2.92 µM pepstatin A, 21 µM leupeptin, and 3 µM aprotinin. Cells were homogenized and centrifuged at 600 g for 10 min to remove nuclei, and the supernatants were transferred to a new tube and subsequently centrifuged at 100,000 g for 60 min to pellet membrane fractions. Supernatants were adjusted to 100 mM NaCl and 1% Triton X-100; this fraction was designated S2 and was immunoblotted as described above. The pellets were washed in homogenization buffer and centrifuged at 100,000 g for 30 min, and the pellets were solubilized in 150 µl of homogenization buffer containing 100 mM NaCl and 1% Triton X-100; this fraction was designated P2 and was immunoblotted as described above.
In vitro deglycosylation. Deglycosylation assays were carried out with peptide N-glycosidase F (PNGase) and endoglycosidase H (Endo H) using proprietary provided buffers (New England Biolabs, Ipswich, MA). Briefly, cells were lysed as described above and centrifuged at 13,000 rpm for 25 min, and the supernatants were mixed with denaturation buffer (2–60 µl cell lysate). Samples were boiled for 10 min, divided into thirds, and treated with either G7/NP-40 buffer and PNGase, G5 buffer and Endo H, or with no enzymes. After incubation, all samples were boiled for 5 min, subjected to SDS-PAGE, and immunoblotted, as described above.
Statistical analysis. The density of proteins in images of Western blots was quantitated using ImageJ. Statistical comparisons were made by Student's t-test or one-way ANOVA (Student-Newman-Keul's) using SigmaStat, with between-group P values <0.05 considered statistically significant.
| RESULTS |
|---|
|
|
|---|
125 and 90 kDa (Fig. 1A), whereas expression of the COOH-terminal insertion clone (mCLCA4-713) resulted in immunoreactive bands of 125 and 40 kDa, and NH2- and COOH-fragment Myc insertion clones (mCLCA4-21, 713Myc) produced all three bands (Fig. 1A). In time course experiments in which the proportion of 90-kDa relative to 125-kDa protein (90- to 125-kDa ratio) was examined 24 and 48 h following transfection, the proportion of 90-kDa protein increased progressively with time (Fig. 1B; see also Fig. 3A). These results are consistent with the endocytic cleavage of the 125-kDa full-length peptide to 90- and 40-kDa NH2- and COOH-terminal peptides, respectively.
|
|
Secretion of the 90- and 40-kDa COOH-terminal mCLCA4 peptides. Because previous reports indicated that NH2- and COOH-terminal fragments from some CLCAs are secreted (3, 6, 8), we attempted to immunoprecipitate Myc-tagged mCLCA proteins from media surrounding transfected cells. As shown in Fig. 2A, Western blots of the immunoprecipitates revealed the presence of the 90-kDa NH2- and 40-kDa COOH-terminal peptides in the cell media. Moreover, exposure of cells to the ER-Golgi transport inhibitor BFA (2 µg/ml for 24 h) markedly reduced the amount of protein present in the media, whereas washout of BFA (4 h) reversed this effect (Fig. 2B). Thus mCLCA4 is processed into two peptides, both of which are secreted and associate with the plasma membrane.
|
LL and RxR sequences regulate ER retention and export of mCLCA4. The alteration in proteolytic processing observed in the mCLCA4-21MycAA mutant suggested the possibility that the RARSPT sequence might be involved in the regulation of ER export, resulting in less efficient export of the parent 125-kDa full-length protein and an attendant decrease in processing to the 90-kDa NH2-terminal fragment. Examination of the neighboring sequence indicated the presence of two upstream LLs that have been shown to regulate ER retention and export in combination with an RxR motif (11), which is contained within the targeted RARSPT sequence. The RAR sequence is shared between mCLCA1, mCLCA2, and mCLCA4 but is not preserved in other mCLCAs, whereas the LL sequences are unique to mCLCA4. LI sequences are found in mCLCA1 and mCLCA2 (Fig. 4A), however, and may play a similar role. In other proteins, cytoplasmic LLs appear to serve as an ER export or forward trafficking signal through the binding of chaperones, whereas the RxR is an ER retention signal (11). To determine the relevance of these sequences, we created additional mutants that eliminated the more COOH-terminal LL (2L/2A), both LL sequences (4L/4A), the RxR sequence (2R/2A), or both the LL and RxR sequences (4L2R/6A) (Fig. 4B). Mutation of either the COOH-terminal LL or both LL pairs prevented forward trafficking of mCLCA4 proteins to the cell membrane (Fig. 4C), indicating a potent role of these sequences in forward trafficking. However, mutation of the putative RxR retention sequence also resulted in perinuclear localization of mCLCA4 (Fig. 4C).
|
|
|
| DISCUSSION |
|---|
|
|
|---|
125 kDa that is proteolytically cleaved into large NH2-terminal (90-kDa) and smaller COOH-terminal (40-kDa) fragments. The data are consistent with cleavage within the ER or early in the trans Golgi network, since the full-length mClCA4 protein displays an ER-like immunoreactive pattern, does not traffic to the plasma membrane, and is immaturely glycosylated (Fig. 5D). Both the NH2- and COOH-terminal cleavage products are secreted and found in the media, where they rapidly associate with the plasma membrane, and proteins isolated from cell lysates display a mature glycosylation pattern (Figs. 1B and 5A), further suggesting that only the proteolytic products are forward trafficked beyond the ER. The topology and cellular fate of CLCA proteins has undergone substantial refinement since the initial modeling indicating multiple transmembrane segments (1, 7, 9). More recent structural analysis indicates a single COOH-terminal transmembrane segment (22) and a conserved NH2-terminal hydrolase domain (19). This prediction has been supported by experimental data indicating the secretion of a CLCA fragment in the extracellular space (3, 6, 14), although differences exist as to whether the NH2-terminal fragment (6) or both the NH2- and COOH-terminal fragments (3) are secreted extracellularly, with the latter data inconsistent with a single transmembrane domain. For mCLCA3, the two proteins are reported to remain physically associated and secreted in the extracellular space (14), whereas the COOH-terminal fragment of the highly related human homolog hCLCA1 does not appear to be associated with the secreted NH2-terminal cleaved peptide and is not found in the extracellular media (6).
Based on results from hCLCA2, Elble et al. (3) have suggested a general model of CLCA processing in which the full-length precursor is transported to the cell surface where it undergoes cleavage by an endopeptidase, resulting in release of the NH2-terminal fragment, whereas the COOH-terminal fragment with its transmembrane segment remains as an integral membrane protein. Our data are in general consistent with this model, although it appears that both proteins remain associated with the plasma membrane and that the full-length precursor of mCLCA4 does not traffic to the plasma membrane, since the 125-kDa fragment is sensitive to Endo H digestion (Fig. 5, A, B, and D). Also, unlike hCLCA2, we were unable to demonstrate tight association between the two fragments by coimmunoprecipitation (data not shown).
We have also extended these observations by determining the luminal motifs that regulate trafficking of mCLCA4. Kalandze et al. (11) described cytosolic RxR retention and LL forward trafficking signals regulating the trafficking of GLT-1, an intrinsic membrane protein. Interestingly, mutation of all of the LL motifs in GLT-1 was required to abolish forward trafficking, since 2L/2A and 4L/4A proteins were still maturely glycosylated and inserted in the plasma membrane. The 6L/6A GLT-1 mutation resulted in ER trapping but also resulted in markedly less full-length protein in the lysate, suggesting misfolding and degradation. By contrast, secretion of the 90-kDa NH2-terminal peptide was completely inhibited in 2L/2A and 4L/4A mutants of the luminal protein mCLCA4, and high amounts of ER-trapped 125-kDa protein were observed (Fig. 5B). Mutation of the RxRs also produced an apparent loss of 90-kDa product in the protein lysate; however, protein was readily detected in the cell medium, suggesting augmented forward trafficking associated with loss of the RxR retention signal. The apparent absence of the 90-kDa peptide from the plasma membrane suggests that the RxR motif may also be required for surface association. Chimeric constructs clearly demonstrated the role of the LL sequences in forward trafficking (Fig. 6, B and C), and the prominent vesicular pattern of EGFP expression in 4L/4A mutants confirms the importance of these sequences as retention signals. Because CLCA proteins appear to undergo distinct processing (3, 6, 14), these motifs may underlie significant functional differences in these family members. Studies designed to determine the function of the separate membrane-associated fragments should provide more clarity with respect to the role of CLCAs in ion transport and secretion.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
* C. Huan and K. S. Greene contributed equally to this study. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Elble RC, Ji G, Nehrke K, DeBiasio J, Kingsley PD, Kotlikoff MI, Pauli BU. Molecular and functional characterization of a murine calcium-activated chloride channel expressed in smooth muscle. J Biol Chem 277: 18586–18591, 2002.
3. Elble RC, Walia V, Cheng HC, Connon CJ, Mundhenk L, Gruber AD, Pauli BU. The putative chloride channel hCLCA2 has a single C-terminal transmembrane segment. J Biol Chem 281: 29448–29454, 2006.
4. Elble RC, Widom J, Gruber AD, Abdel-Ghany M, Levine R, Goodwin A, Cheng HC, Pauli BU. Cloning and characterization of lung-endothelial cell adhesion molecule-1 suggest it is an endothelial chloride channel. J Biol Chem 272: 27853–27861, 1997.
5. Ellgaard L, Helenius A. Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 4: 181–191, 2003.[CrossRef][Web of Science][Medline]
6. Gibson A, Lewis AP, Affleck K, Aitken AJ, Meldrum E, Thompson N. hCLCA1 and mCLCA3 are secreted non-integral membrane proteins and therefore are not ion channels. J Biol Chem 280: 27205–27212, 2005.
7. Gruber AD, Elble RC, Ji HL, Schreur KD, Fuller CM, Pauli BU. Genomic cloning, molecular characterization, and functional analysis of human CLCA1, the first human member of the family of Ca2+-activated Cl- channel proteins. Genomics 54: 200–214, 1998.[CrossRef][Web of Science][Medline]
8. Gruber AD, Pauli BU. Molecular cloning and biochemical characterization of a truncated, secreted member of the human family of Ca2+-activated Cl- channels. Biochim Biophys Acta 1444: 418–423, 1999.[Medline]
9. Gruber AD, Schreur KD, Ji HL, Fuller CM, Pauli BU. Molecular cloning and transmembrane structure of hCLCA2 from human lung, trachea, and mammary gland. Am J Physiol Cell Physiol 276: C1261–C1270, 1999.
10. Hebert DN, Garman SC, Molinari M. The glycan code of the endoplasmic reticulum: asparagine-linked carbohydrates as protein maturation and quality-control tags. Trends Cell Biol 15: 364–370, 2005.[CrossRef][Web of Science][Medline]
11. Kalandadze A, Wu Y, Fournier K, Robinson MB. Identification of motifs involved in endoplasmic reticulum retention-forward trafficking of the GLT-1 subtype of glutamate transporter. J Neurosci 24: 5183–5192, 2004.
12. Leverkoehne I, Holle H, Anton F, Gruber AD. Differential expression of calcium-activated chloride channels (CLCA) gene family members in the small intestine of cystic fibrosis mouse models. Histochem Cell Biol 126: 239–250, 2006.[CrossRef][Medline]
13. Loewen ME, Forsyth GW. Structure and function of CLCA proteins. Physiol Rev 85: 1061–1092, 2005.
14. Mundhenk L, Alfalah M, Elble RC, Pauli BU, Naim HY, Gruber AD. Both cleavage products of the mCLCA3 protein are secreted soluble proteins. J Biol Chem 281: 30072–30080, 2006.
15. Nakanishi A, Morita S, Iwashita H, Sagiya Y, Ashida Y, Shirafuji H, Fujisawa Y, Nishimura O, Fujino M. Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma. Proc Natl Acad Sci USA 98: 5175–5180, 2001.
16. Nara M, Dhulipala PD, Wang YX, Kotlikoff MI. Reconstitution of beta-adrenergic modulation of large conductance, calcium-activated potassium (maxi-K) channels in Xenopus oocytes. Identification of the camp-dependent protein kinase phosphorylation site. J Biol Chem 273: 14920–14924, 1998.
17. Patel AC, Morton JD, Kim EY, Alevy Y, Swanson S, Tucker J, Huang G, Agapov E, Phillips TE, Fuentes ME, Iglesias A, Aud D, Allard JD, Dabbagh K, Peltz G, Holtzman MJ. Genetic segregation of airway disease traits despite redundancy of calcium-activated chloride channel family members. Physiol Genomics 25: 502–513, 2006.
18. Pauli BU, Abdel-Ghany M, Cheng HC, Gruber AD, Archibald HA, Elble RC. Molecular characteristics and functional diversity of CLCA family members. Clin Exp Pharmacol Physiol 27: 901–905, 2000.[CrossRef][Web of Science][Medline]
19. Pawlowski K, Lepisto M, Meinander N, Sivars U, Varga M, Wieslander E. Novel conserved hydrolase domain in the CLCA family of alleged calcium-activated chloride channels. Proteins 63: 424–439, 2006.[CrossRef][Web of Science][Medline]
20. Ritzka M, Stanke F, Jansen S, Gruber AD, Pusch L, Woelfl S, Veeze HJ, Halley DJ, Tummler B. The CLCA gene locus as a modulator of the gastrointestinal basic defect in cystic fibrosis. Hum Genet 115: 483–491, 2004.[CrossRef][Web of Science][Medline]
21. Teasdale RD, Jackson MR. Signal-mediated sorting of membrane proteins between the endoplasmic reticulum and the golgi apparatus. Annu Rev Cell Dev Biol 12: 27–54, 1996.[CrossRef][Web of Science][Medline]
22. Whittaker CA, Hynes RO. Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere. Mol Biol Cell 13: 3369–3387, 2002.
23. Zhou Y, Dong Q, Louahed J, Dragwa C, Savio D, Huang M, Weiss C, Tomer Y, McLane MP, Nicolaides NC, Levitt RC. Characterization of a calcium-activated chloride channel as a shared target of Th2 cytokine pathways and its potential involvement in asthma. Am J Respir Cell Mol Biol 25: 486–491, 2001.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |